テネシーにおける過体重の臨床試験
テネシー内の拠点で、過体重に関する25件の研究が参加者を募集しています。
テネシー内の都市
公式研究テキスト（英語）
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Holston Medical Group - Bristol /ID# 282045, Bristol
- New Phase Research & Development /ID# 282131, Knoxville
- Summit Medical Group- Halls Family Physicians /ID# 282435, Knoxville
- 他1件
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/10/01更新 · NCT07752979AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- M3 Wake Research Chattanooga, Chattanooga
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07533175A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- LifeDoc Health, Memphis
被験者募集中第3相
8歳〜18歳 · 全性別 · 2026/09/30更新 · NCT07253285Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- AMR Clinical, Nashville
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/28更新 · NCT07837973A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- New Phase Research and Development, Knoxville
- Clinical Research Associates Inc, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07794579A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Vanderbilt Health One Hundred Oaks, Nashville
被験者募集中第3相
6歳〜17歳 · 全性別 · 2026/09/24更新 · NCT06672549Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastroenterology Center Of The Midsouth, Cordova
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastroenterology Center Of The Midsouth, Cordova
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- AMR Clinical, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07321886Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Stern Cardiovascular Foundation Inc, Germantown
- Accellacare of Knoxville, Knoxville
- Cardiovascular Research of Knoxville North Knoxville Medical Center, Powell
- 他1件
被験者募集中第3相
45歳〜99歳 · 全性別 · 2026/09/22更新 · NCT07037433A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Quality Medical Research, Nashville
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/22更新 · NCT07589608A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Franklin
- Research Site, Jackson
- Research Site, Knoxville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07784270A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Memphis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Memphis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Innovative Clinical Research, Clarksville
- Clinical Research Associates, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/14更新 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Nashville
被験者募集中第3相健康なボランティア歓迎
18歳〜79歳 · 全性別 · 2026/09/11更新 · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Quality Medical Research, Nashville
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/08更新 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- DelRicht Research - Thompson's Station, Smyrna
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06857942Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Chattanooga
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- New Phase Research and Development, Knoxville
被験者募集中第3相
18歳〜99歳 · 全性別 · 2026/09/03更新 · NCT07684235Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailea Clinical Site, Memphis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT07284901A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Kingsport
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/25更新 · NCT07784725Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Knoxville
被験者募集中第3相
18歳〜79歳 · 全性別 · 2026/08/10更新 · NCT07654361Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
- Holston Medical Group_Bristol, Bristol
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/25更新 · NCT07607587A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
- MBX Biosciences Investigational Site, Knoxville
被験者募集中第1相
18歳〜65歳 · 全性別 · 2026/06/09更新 · NCT07142707ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。